Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say
This article was originally published in The Gray Sheet
While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions
You may also be interested in...
The industry group's future advocacy around legal and regulatory reforms affecting product sponsor communications with payers and health-care providers will align with four bioethical considerations.
The Duke-Margolis Center has released a list of policy changes that experts argue could improve how off-label communication is disseminated. Among the proposals is a third-party organization to vet off-label communication and a tiered labeling system.
Judge extends date for agency response to firm's complaint as parties continue settlement talks; case reveals two chinks in FDA’s off-label regulatory regime armor, former FDA advisor says.